News Nektar Therapeutics

Equities

NKTR

US6402681083

Real-time Estimate Cboe BZX Other stock markets 01:30:53 2024-04-24 pm EDT			5-day change	1st Jan Change
1.405 ^USD	-1.06%		+4.07%	+148.67%

01:00pm	Biolojic Design Announces Nektar Therapeutics Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases	CI
Mar. 19	Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biolojic Design Announces Nektar Therapeutics Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases	07:00am	CI
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune and Inflammatory Disease Virtual Conference	Mar. 25	AQ
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	Mar. 22	PR
Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC	Mar. 18	CI
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata	Mar. 05	MT
Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating	Mar. 05	MT
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata	Mar. 05	PR
Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata	Mar. 05	CI
Transcript : Nektar Therapeutics, Q4 2023 Earnings Call, Mar 04, 2024	Mar. 04
Nektar: Q4 Earnings Snapshot	Mar. 04	AQ
Nektar Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04	CI
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q4 Revenue $23.9M, vs. Street Est of $21.4M	Mar. 04	MT
Nektar Therapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 04	CI
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX	Mar. 04	PR
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
Nektar Therapeutics announced that it expects to receive $30 million in funding from TCG Crossover Management, LLC	Mar. 03	CI
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference	Feb. 27	PR
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets	Feb. 26	PR
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer	Jan. 22	MT
Transcript : Nektar Therapeutics Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM	Jan. 10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Nektar Therapeutics

Equities

NKTR

US6402681083

Summary

Filters